BG Medicine Inc.

BG Medicine Welcomes Inclusion of Galectin-3 as Biomarker of Myocardial Fibrosis in 2013 ACCF/AHA Guideline for Management of Heart Failure

WALTHAM, Mass., June 12, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that galectin-3 testing has been recognized for the first time in the newly issued 2013 American College of Cardiology Foundation and the American Heart Association (ACCF/AHA) Guideline for the Management of Heart Failure. The ACCF/AHA Guideline is designed to assist clinicians in selecting the best management strategy for individual patients and provides expert analysis of data on prevention, diagnosis, risk stratification, and treatment.

BG Medicine Inc.

BG Medicine Announces Late-Breaker Oral Presentation of New Data on the BGM Galectin-3(R) Test in Heart Failure

WALTHAM, Mass., May 28, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced the presentation of new clinical research data on the BGM Galectin-3® test in heart disease at the 2013 European Society of Cardiology Heart Failure Congress (ESC-HF) in Lisbon, Portugal. Among the highlights was a late-breaking oral presentation of results from the Aldo-DHF Biomarker Substudy which demonstrated the usefulness of galectin-3 testing for assessing functional capacity and clinical prognosis in patients diagnosed with a form of heart failure known as Heart Failure with Preserved Ejection Fraction (HFpEF).

BG Medicine Inc.

BG Medicine, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

WALTHAM, Mass., May 10, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, announced today that the company granted a stock option to Paul Sohmer, M.D., the company's newly appointed President and Chief Executive Officer, on May 10, 2013. The stock option was granted as an inducement material to Dr. Sohmer's acceptance of employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), which, under these circumstances, provides an exception to the stockholder approval requirements and allows for the grant of this stock option to be made outside the company's stockholder-approved equity plans.

BG Medicine Inc.

BG Medicine Appoints Dr. Paul Sohmer as Chief Executive Officer

WALTHAM, Mass., May 9, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today announced that it has appointed Paul Sohmer, M.D., as its President & Chief Executive Officer and a member of its Board of Directors, effective immediately. Dr. Sohmer, who brings more than 25 years of experience leading the growth of commercial-stage companies focused on diagnostics, laboratory services, and medical devices, replaces Eric Bouvier as CEO.

BG Medicine Inc.

BG Medicine Reports 2013 First Quarter Financial Results

BG Medicine Inc.

Trenton Health Team Adopts Novel Diagnostic Tool, BGM Galectin-3(R) Test, to Reduce Hospital Readmissions

TRENTON, N.J. and WALTHAM, Mass., May 8, 2013 (GLOBE NEWSWIRE) -- The Trenton Health Team (THT) and BG Medicine (Nasdaq:BGMD) today announced that THT has adopted the BGM Galectin-3® test throughout its organization to identify patients at near term risk for heart failure rehospitalization. THT is a community health improvement collaborative that serves the six zip codes of Trenton, New Jersey and is in the process of developing a Medicaid accountable care organization (ACO).

BG Medicine Inc.

BG Medicine to Announce First Quarter 2013 Financial Results and Host Conference Call on Thursday, May 9, 2013

WALTHAM, Mass., May 2, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that the company will host a conference call and webcast on Thursday, May 9 at 8:30 a.m. Eastern Time to discuss its first quarter 2013 financial results.  The call and webcast will follow the release of first quarter financial results before the market opens.

BG Medicine Inc.

BG Medicine Welcomes CE Mark for Galectin-3 Test

WALTHAM, Mass., April 10, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, welcomed the announcement today that Abbott has obtained a CE Mark for the Galectin-3 assay run on the ARCHITECT immunochemistry platform.

BG Medicine Inc.

BG Medicine Reports Fourth Quarter and Full Year 2012 Financial Results and Provides 2013 Outlook

WALTHAM, Mass., March 13, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a diagnostics company focused on the development and commercialization of novel cardiovascular tests, today reported financial results for the fourth quarter and full year ended December 31, 2012 and provided an update on its progress in expanding the commercial adoption of its innovative diagnostic tests for cardiovascular disease.

BG Medicine Inc.

BG Medicine to Announce Fourth Quarter and Year-End 2012 Financial Results and Host Conference Call on Wednesday, March 13, 2013

WALTHAM, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that the company will host a conference call and webcast on Wednesday, March 13 at 8:30 a.m. Eastern Time to discuss its fourth quarter and year-end 2012 financial results. The call and webcast will follow the release of the fourth quarter financial results before the market opens.